Advertisement

Urine Beta2-Microglobulin Is an Early Marker of Renal Involvement in LPI

  • Mari KärkiEmail author
  • Kirsti Näntö-Salonen
  • Harri Niinikoski
  • Laura M. Tanner
Research Report
Part of the JIMD Reports book series (JIMD, volume 25)

Abstract

Objective: Lysinuric protein intolerance (LPI) is a rare autosomal recessive disorder affecting the transport of cationic amino acids. It has previously been shown that approximately one third of the Finnish LPI patients have impaired renal function. The aim of this study was to analyse in detail urine beta2-microglobulin values, renal dysfunction, oral l-citrulline doses and plasma citrulline concentrations in Finnish LPI patients.

Methods and results: Of the 41 Finnish LPI patients, 56% had proteinuria and 53% hematuria. Mean plasma creatinine concentration was elevated in 48%, serum cystatin C in 62%, and urine beta2-microglobulin in 90% of the patients. Seventeen per cent of the patients developed ESRD, and five of them received a kidney transplant.

l-citrulline doses and fasting plasma citrulline concentrations were similar in adult LPI patients with decreased and normal GFR (mean ± SD 79.5 ± 29.2 vs. 82.4 ± 21.9 mg/kg/day, P = 0.619, and 80.3 ± 20.1 vs. 64.8 ± 23.0 μmol/l, P = 0.362, respectively).

Conclusions: Urine beta2-microglobulin is a sensitive early marker of renal involvement, and it should be monitored regularly in LPI patients. Weight-based oral l-citrulline doses and plasma citrulline concentrations were not associated with renal function. LPI patients with ESRD were successfully treated with dialysis and kidney transplantation.

Keywords

Glomerular Filtration Rate Serum Cystatin Normal Glomerular Filtration Rate Lysinuric Protein Intolerance Urine Dipstick Test 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.

Abbreviations

CKD-EPI

The Chronic Kidney Disease Epidemiology Collaboration (CKD-EPI) equation

ESRD

End-stage renal disease

GFR

Glomerular filtration rate

LPI

Lysinuric protein intolerance

MDRD

Modification of diet in renal disease

SLC7A7

Solute carrier family 7, member 7

y+LAT-1

y+l amino acid transporter-1

Notes

Acknowledgements

We thank Tero Vahlberg for help in the analysis of the l-citrulline doses.

References

  1. Perheentupa J, Visakorpi J (1965) Protein intolerance with deficient transport of basic aminoacids. Another inborn error of metabolism. Lancet 2:813–816CrossRefPubMedGoogle Scholar
  2. Norio R, Perheentupa J, Kekomäki M, Visakorpi J (1971) Lysinuric protein intolerance, an autosomal recessive disease. A genetic study of 10 Finnish families. Clin Genet 2:214–222Google Scholar
  3. Rajantie J, Simell O, Perheentupa J (1980a) Basolateral-membrane transport defect for lysine in lysinuric protein intolerance. Lancet 1:1219–1221CrossRefPubMedGoogle Scholar
  4. Borsani G, Bassi MT, Sperandeo MP et al (1999) SLC7A7, encoding a putative permease-related protein, is mutated in patients with lysinuric protein intolerance. Nat Genet 21:297–301CrossRefPubMedGoogle Scholar
  5. Torrents D, Mykkänen J, Pineda M et al (1999) Identification of SLC7A7, encoding y+LAT-1, as the lysinuric protein intolerance gene. Nat Genet 21:293–296CrossRefPubMedGoogle Scholar
  6. Torrents D, Estévez R, Pineda M et al (1998) Identification and characterization of a membrane protein (y+L amino acid transporter-1) that associates with 4F2hc to encode the amino acid transport activity y+L. A candidate gene for lysinuric protein intolerance. J Biol Chem 273:32437–32445CrossRefPubMedGoogle Scholar
  7. Incerti B, Andria G, Parenti G et al (1993) Lysinuric protein intolerance – studies on 17 Italian patients. Am J Hum Genet 53:908Google Scholar
  8. Koizumi A, Shoji Y, Nozaki J et al (2000) A cluster of lysinuric protein intolerance (LPI) patients in a northern part of Iwate. Japan due to a founder effect. The Mass Screening Group. Hum mutat 16:270–271CrossRefPubMedGoogle Scholar
  9. Simell O, Perheentupa J, Rapola J, Visakorpi JK, Eskelin LE (1975) Lysinuric protein intolerance. Am J Med 59:229–240CrossRefPubMedGoogle Scholar
  10. Simell O (2001) Lysinuric protein intolerance and other cationic aminoacidurias. In: Scriver CS, Beaucert AL, Sly WS, Valle D (eds) The metabolic and molecular bases of inherited disease. McGraw-Hill, New York, pp 4933–4956Google Scholar
  11. Tanner L, Niinikoski H, Näntö-Salonen K, Simell O (2010) Combined hyperlipidemia in patients with lysinuric protein intolerance. J Inherit Metab Dis 33:145–150CrossRefGoogle Scholar
  12. Lukkarinen M, Parto K, Ruuskanen O et al (1999) B and T cell immunity in patients with lysinuric protein intolerance. Clin Exp Immunol 116:430–434CrossRefPubMedPubMedCentralGoogle Scholar
  13. Tanner L, Näntö-Salonen K, Rashed MS et al (2008) Carnitine deficiency and l-carnitine supplementation in lysinuric protein intolerance. Metab Clin Exp 57:549–554CrossRefPubMedGoogle Scholar
  14. DiRocco M, Garibotto G, Rossi GA et al (1993) Role of haematological, pulmonary and renal complications in the long-term prognosis of patients with lysinuric protein intolerance. Eur J Pediatr 152:437–440CrossRefPubMedGoogle Scholar
  15. Parto K, Kallajoki M, Aho H, Simell O (1994) Pulmonary alveolar proteinosis and glomerulonephritis in lysinuric protein intolerance: case reports and autopsy findings of four pediatric patients. Hum Pathol 25:400–407CrossRefPubMedGoogle Scholar
  16. Tanner L, Näntö-Salonen K, Niinikoski H et al (2007) Nephropathy advancing to end-stage renal disease: a novel complication of lysinuric protein intolerance. J Pediatr 150:631–634CrossRefPubMedGoogle Scholar
  17. Creswell P, Springer T, Strominger JL et al (1974) Immunological identity of the small subunit of HLA antigens and b2-microglobulin and its turnover on the cell membrane. Proc Nat Acad Sci USA 71:2123–2207CrossRefGoogle Scholar
  18. Bianchi C, Donadio C, Tramonti G, Consani C, Lorusso P, Rossi G (2001) Reappraisal of serum β2-microglobulin as marker of GFR. Ren Fail 23(3–4):419–429CrossRefPubMedGoogle Scholar
  19. Wibell L, Evrin PE, Berggård I (1973) Serum b2-microglobulin in renal disease. Nephron 10:320–331CrossRefPubMedGoogle Scholar
  20. Trollfors B, Norrby R (1981) Estimation of glomerular filtration rate by serum creatinine and serum b2-microglobulin. Nephron 28:196–199CrossRefPubMedGoogle Scholar
  21. Acchiardo S, Kraus AP, Jennings BR (1989) B2-microglobulin levels in patients with renal insufficiency. Amer J Kid Dis 13:70–74CrossRefGoogle Scholar
  22. Shea PH, Maher JF, Horak E (1981) Prediction of glomerular filtration rate by serum creatinine and b2-microglobulin. Nephron 29:30–35CrossRefPubMedGoogle Scholar
  23. Gauthier C, Nquyen-Simonnet H, Vincent C, Revillard JP, Pellet MC (1984) Renal tubular absorption of beta 2 microglobulin. Kidney Int 26(2):170–175CrossRefPubMedGoogle Scholar
  24. Kamoda T, Nagai Y, Shigeta M et al (1998) Lysinuric protein intolerance and systemic lupus erythematosus. Eur J Pediatr 157:130–131CrossRefPubMedGoogle Scholar
  25. Zager RA, Johannes G, Tuttle SE, Sharma HM (1983) Acute amino acid nephrotoxicity. J Lab Clin Med 101:130–140PubMedGoogle Scholar
  26. Rajantie J, Simell O, Perheentupa J (1981) Lysinuric protein intolerance. Basolateral transport defect in renal tubuli. J Clin Invest 67(4):1078–1082CrossRefPubMedPubMedCentralGoogle Scholar
  27. Rajantie J, Simell O, Rapola J, Perheentupa J (1980b) Lysinuric protein intolerance: a two-year trial of dietary supplementation therapy with citrulline and lysine. J Pediatr 97(6):229–240CrossRefGoogle Scholar
  28. Awrich AE, Stackhouse WJ, Cantrell JE, Patterson JH, Rudman D (1975) Hyperdibasicaminoaciduria, hyperammonemia, and growth retardation: Treatment with arginine, lysine, and citrulline. J Pediatr 87:731–738CrossRefPubMedGoogle Scholar
  29. Lukkarinen M, Näntö-Salonen K, Pulkki K, Aalto M, Jahnukainen T, Simell O (2006) Renal Complications in lysinuric protein intolerance. In: Lukkarinen M (ed) Improvements of the treatment in lysinuric protein intolerance. Annales Universitatis Turkuensis. Yliopistopaino, Helsinki, pp 52–80Google Scholar
  30. Sebastio G, Sperandeo MP, Andria G (2011) Lysinuric protein intolerance: reviewing concepts on a multisystem disease. Am J Med Genet C Semin Med Genet 157:54–62CrossRefGoogle Scholar
  31. Alderton WK, Cooper CE, Knowles RG (2001) Nitric oxide synthases: structure, function and inhibition. Biochem J 357:593–615CrossRefPubMedPubMedCentralGoogle Scholar
  32. Mori M (2007) Regulation of nitric oxide synthesis and apoptosis by arginase and arginine recycling. J Nutr 137:1616S–1620SPubMedGoogle Scholar
  33. Morris S (2007) Arginine metabolism: boundaries of our knowledge. J Nutr 137:1602S–1609SPubMedGoogle Scholar
  34. Ogier de Baulny H, Schiff M, Dionisi-Vici C (2012) Lysinuric protein intolerance (LPI): a multi organ disease by far more complex than a classic urea cycle disorder. Mol Genet Metab 106:12–17CrossRefPubMedGoogle Scholar

Copyright information

© SSIEM and Springer-Verlag Berlin Heidelberg 2015

Authors and Affiliations

  • Mari Kärki
    • 1
    Email author
  • Kirsti Näntö-Salonen
    • 1
  • Harri Niinikoski
    • 2
  • Laura M. Tanner
    • 3
  1. 1.Department of PediatricsUniversity of TurkuTurkuFinland
  2. 2.Department of Pediatrics and PhysiologyUniversity of TurkuTurkuFinland
  3. 3.Department of Medical Biochemistry and GeneticsUniversity of TurkuTurkuFinland

Personalised recommendations